Videos

Kereiakes discusses the potential of lerodalcibep for adults with hypercholesterolemia and high LDL-C, highlighting recent FDA approval.

New phase 3 data support the FDA approval of lumateperone, showing early efficacy and favorable tolerability as an adjunctive treatment for MDD.

Brenner describes shortcomings of pharmacologic CIC options and reviews real-world data on the Vibrant System’s benefits in this context.

What are your impressions of the Phase 2b data of zasocitinib in psoriasis, particularly in terms of Psoriasis Area and Severity Index (PASI) responses, dose-dependent effects, and tolerability? How do you see these results influencing your real-world patient selection?

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Singhal reviews new AGA survey data on public perceptions of obesity as a chronic disease and describes opportunities to improve care.

Cohran describes her research on characteristics linked to treatment response to teduglutide for short bowel syndrome-associated intestinal failure.

End-of-study analysis from the HOPE-B trial shows durable endogenous FIX expression, reduced annualized bleeding rates, and a favorable safety profile.

Nedelkopoulou emphasizes the importance of structured and multidisciplinary transition programs for young patients with IBD and HPB disease.

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Mallon explains the shared risks linking celiac disease and type 1 diabetes and why early screening improves outcomes.

Explore the latest advancements in kidney stone treatment, focusing on suction technology and its impact on surgical outcomes and patient safety.

Cohen cites past failures with risk-based hepatitis B vaccination and voices concerns about the CDC APIC vote for individual-based decision-making.

Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Explore the distinct role of TIC-2 in psoriasis and how selective inhibition offers targeted treatment advantages over traditional JAK inhibitors.

This December 4 episode of Skin of Color Savvy highlights takeaways from the SOCS Virtual Media Day.

Recent advancements in HAE treatments offer hope, but experts stress the need for more pediatric options and diverse therapies.

Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

Barr discusses the means to encourage systemic adoption of low dose CT scans to help curb the deadliest cancer in the US.

Sorajja discusses the results of this groundbreaking trial investigating a new implant for patients with severe mitral annular calcification.

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.

Rosovsky discusses the revolutionary new therapy’s potential to revolutionize the field of pulmonary embolism treatment.

O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.